Exelixis (EXEL) Cash from Investing Activities (2010 - 2026)

Exelixis' (EXEL) quarterly Cash from Investing Activities came in at -$51.1 million in Q2 2026, down 202.62% year-on-year from $49.8 million in Q2 2025, and down 287.47% quarter-over-quarter from $27.2 million in Q1 2026.

Exelixis (EXEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Exelixis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$51.1 million for Q2 2026.

  • On a quarterly basis, Cash from Investing Activities fell 202.62% year-over-year to -$51.1 million in Q2 2026; TTM through Apr 2026 was $249.6 million, a 239.59% increase from a year earlier, with the FY2026 full-year figure at $350.4 million, up 400.08% from the prior year.
  • Cash from Investing Activities slipped to -$51.1 million in Q2 2026 per EXEL's latest filing, from $27.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $248.0 million in Q3 2025 and bottomed at -$245.8 million in Q4 2022.
  • The 5-year median for Cash from Investing Activities is -$49.6 million (2023), against an average of -$21.7 million.
  • Across the five-year window, Cash from Investing Activities tumbled 1782.67% in 2022 and soared 325.43% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$245.8 million in 2022, then surged by 125.12% to $61.7 million in 2023, then sank by 451.73% to -$217.1 million in 2024, then jumped by 111.7% to $25.4 million in 2025, then sank by 301.02% to -$51.1 million in 2026.
  • Per Business Quant, the three latest EXEL Cash from Investing Activities figures stand at -$51.1 million (Q2 2026), $27.2 million (Q1 2026), and $25.4 million (Q4 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn -51.07 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 -51.07 Mn
Apr 3, 2026 -51.07 Mn
Jan 2, 2026 27.24 Mn
Jan 2, 2026 27.24 Mn
Oct 3, 2025 25.41 Mn
Oct 3, 2025 25.41 Mn
Jul 4, 2025 248.03 Mn
Jul 4, 2025 248.03 Mn
Apr 4, 2025 49.76 Mn
Apr 4, 2025 49.76 Mn
Jan 3, 2025 -93.20 Mn
Jan 3, 2025 -93.20 Mn
Sep 27, 2024 -217.15 Mn
Sep 27, 2024 -217.15 Mn
Jun 28, 2024 81.77 Mn
Jun 28, 2024 81.77 Mn
Mar 29, 2024 111.79 Mn
Mar 29, 2024 111.79 Mn
Dec 29, 2023 61.74 Mn
Dec 29, 2023 61.74 Mn